|
1.
|
Boyd KP, Korf BR and Theos A:
Neurofibromatosis type 1. J Am Acad Dermatol. 61:1–14. 2009.
View Article : Google Scholar
|
|
2.
|
Ferner RE: Neurofibromatosis 1. Eur J Hum
Genet. 15:131–138. 2007. View Article : Google Scholar
|
|
3.
|
Cawthon RM, Weiss R, Xu GF, et al: A major
segment of the neurofibromatosis type 1 gene: cDNA sequence,
genomic structure, and point mutations. Cell. 62:193–201. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Jett K and Friedman JM: Clinical and
genetic aspects of neurofibromatosis 1. Genet Med. 12:1–11. 2010.
View Article : Google Scholar
|
|
5.
|
Grobmyer SR, Reith JD, Shahlaee A, Bush CH
and Hochwald SN: Malignant peripheral nerve sheath tumor: Molecular
pathogenesis and current management considerations. J Surg Oncol.
97:340–349. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Gottfried ON, Viskochil DH, Fults DW and
Couldwell WT: Molecular, genetic, and cellular pathogenesis of
neurofibromas and surgical implications. Neurosurgery. 58:1–16.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Carroll SL and Stonecypher MS: Tumor
suppressor mutations and growth factor signaling in the
pathogenesis of NF1-associated peripheral nerve sheath tumors: II.
The role of dysregulated growth factor signaling. J Neuropathol Exp
Neurol. 64:1–9. 2005.PubMed/NCBI
|
|
8.
|
Kluwe L, Friedrich R and Mautner VF: Loss
of NF1 allele in Schwann cells but not in fibroblasts derived from
an NF1-associated neurofibroma. Genes Chromosomes Cancer.
24:283–285. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Rutkowski JL, Wu K, Gutmann DH, Boyer PJ
and Legius E: Genetic and cellular defects contributing to benign
tumor formation in neurofibromatosis type 1. Hum Mol Genet.
9:1059–1066. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Serra E, Rosenbaum T, Winner U, et al:
Schwann cells harbor the somatic NF1 mutation in neurofibromas:
evidence of two different Schwann cell subpopulations. Hum Mol
Genet. 9:3055–3064. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Zhu Y, Ghosh P, Charnay P, Burns DK and
Parada LF: Neurofibromas in NF1: Schwann cell origin and role of
tumor environment. Science. 296:920–922. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Jouhilahti EM, Peltonen S, Heape AM and
Peltonen J: The pathoetiology of neurofibromatosis 1. Am J Pathol.
178:1932–1939. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Staser K, Yang FC and Clapp DW: Mast cells
and the neurofibroma microenvironment. Blood. 116:157–164. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Katz D, Lazar A and Lev D: Malignant
peripheral nerve sheath tumour (MPNST): the clinical implications
of cellular signalling pathways. Expert Rev Mol Med. 11:e302009.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Brems H, Beert E, de Ravel T and Legius E:
Mechanisms in the pathogenesis of malignant tumours in
neurofibromatosis type 1. Lancet Oncol. 10:508–515. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Spurlock G, Knight SJ, Thomas N, Kiehl TR,
Guha A and Upadhyaya M: Molecular evolution of a neurofibroma to
malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient:
correlation between histopathological, clinical and molecular
findings. J Cancer Res Clin Oncol. 136:1869–1880. 2010. View Article : Google Scholar
|
|
17.
|
Evans DG, Baser ME, McGaughran J, Sharif
S, Howard E and Moran A: Malignant peripheral nerve sheath tumours
in neurofibromatosis 1. J Med Genet. 39:311–314. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
McCaughan JA, Holloway SM, Davidson R and
Lam WW: Further evidence of the increased risk for malignant
peripheral nerve sheath tumour from a Scottish cohort of patients
with neurofibromatosis type 1. J Med Genet. 44:463–466. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Tucker T, Wolkenstein P, Revuz J, Zeller J
and Friedman JM: Association between benign and malignant
peripheral nerve sheath tumors in NF1. Neurology. 65:205–211. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
McQueen M, MacCollin M, Gusella J and
Plotkin SR: Patient and physician attitudes regarding clinical
trials in neurofibromatosis 1. J Neurosci Nurs. 40:341–345. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Sawada S, Florell S, Purandare SM, Ota M,
Stephens K and Viskochil D: Identification of NF1 mutations in both
alleles of a dermal neurofibroma. Nat Genet. 14:110–112. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Wiest V, Eisenbarth I, Schmegner C, Krone
W and Assum G: Somatic NF1 mutation spectra in a family with
neurofibromatosis type 1: toward a theory of genetic modifiers. Hum
Mutat. 22:423–427. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Kluwe L, Friedrich RE and Mautner VF:
Allelic loss of the NF1 gene in NF1-associated plexiform
neurofibromas. Cancer Genet Cytogenet. 113:65–69. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Rasmussen SA, Overman J, Thomson SA, et
al: Chromosome 17 loss-of-heterozygosity studies in benign and
malignant tumors in neurofibromatosis type 1. Genes Chromosomes
Cancer. 28:425–431. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Upadhyaya M, Kluwe L, Spurlock G, et al:
Germline and somatic NF1 gene mutation spectrum in NF1-associated
malignant peripheral nerve sheath tumors (MPNSTs). Hum Mutat.
29:74–82. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Watanabe T, Oda Y, Tamiya S, Masuda K and
Tsuneyoshi M: Malignant peripheral nerve sheath tumour arising
within neurofibroma. An immunohistochemical analysis in the
comparison between benign and malignant components. J Clin Pathol.
54:631–636. 2001. View Article : Google Scholar
|
|
27.
|
Miller SJ, Rangwala F, Williams J, et al:
Large-scale molecular comparison of human schwann cells to
malignant peripheral nerve sheath tumor cell lines and tissues.
Cancer Res. 66:2584–2591. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Mantripragada KK, Spurlock G, Kluwe L, et
al: High-resolution DNA copy number profiling of malignant
peripheral nerve sheath tumors using targeted microarray-based
comparative genomic hybridization. Clin Cancer Res. 14:1015–1024.
2008. View Article : Google Scholar
|
|
29.
|
Upadhyaya M, Spurlock G, Thomas L, et al:
Microarray-based copy number analysis of neurofibromatosis type-1
(NF1)-associated malignant peripheral nerve sheath tumors reveals a
role for Rho-GTPase pathway genes in NF1 tumorigenesis. Hum Mutat.
33:763–776. 2012. View Article : Google Scholar
|
|
30.
|
Upadhyaya M: Genetic basis of
tumorigenesis in NF1 malignant peripheral nerve sheath tumors.
Front Biosci. 16:937–951. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Carroll SL: Molecular mechanisms promoting
the pathogenesis of Schwann cell neoplasms. Acta Neuropathol.
123:321–348. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Woodruff JM: Pathology of tumors of the
peripheral nerve sheath in type 1 neurofibromatosis. Am J Med
Genet. 89:23–30. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Lee SJ, Park HJ, Kim YH, et al: Inhibition
of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in
neurofibromatosis type 1-associated malignant peripheral nerve
sheath tumor cells. Int J Mol Med. 30:443–450. 2012.PubMed/NCBI
|
|
34.
|
Jeong SY, Gaume B, Lee YJ, et al: Bcl-x(L)
sequesters its C-terminal membrane anchor in soluble, cytosolic
homodimers. EMBO J. 23:2146–2155. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Ferner RE, Huson SM, Thomas N, et al:
Guidelines for the diagnosis and management of individuals with
neurofibromatosis 1. J Med Genet. 44:81–88. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Weiss SW, Langloss JM and Enzinger FM:
Value of S-100 protein in the diagnosis of soft tissue tumors with
particular reference to benign and malignant Schwann cell tumors.
Lab Invest. 49:299–308. 1983.PubMed/NCBI
|
|
37.
|
Arima Y, Hayashi H, Kamata K, et al:
Decreased expression of neurofibromin contributes to
epithelial-mesenchymal transition in neurofibromatosis type 1. Exp
Dermatol. 19:e136–e141. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
McCubrey JA, Steelman LS, Chappell WH, et
al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant
transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Moretti VM, Crawford EA, Staddon AP,
Lackman RD and Ogilvie CM: Early outcomes for malignant peripheral
nerve sheath tumor treated with chemotherapy. Am J Clin Oncol.
34:417–421. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Hiatt KK, Ingram DA, Zhang Y, Bollag G and
Clapp DW: Neurofibromin GTPase-activating protein-related domains
restore normal growth in Nf1−/− cells. J Biol Chem.
276:7240–7245. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Ni Chonghaile T and Letai A: Mimicking the
BH3 domain to kill cancer cells. Oncogene. 27(Suppl 1): S149–S157.
2008.PubMed/NCBI
|
|
42.
|
Brossier NM and Carroll SL: Genetically
engineered mouse models shed new light on the pathogenesis of
neurofibromatosis type I-related neoplasms of the peripheral
nervous system. Brain Res Bull. 88:58–71. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Chai G, Liu N, Ma J, et al: MicroRNA-10b
regulates tumorigenesis in neurofibromatosis type 1. Cancer Sci.
101:1997–2004. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Subramanian S, Thayanithy V, West RB, et
al: Genome-wide transcriptome analyses reveal p53 inactivation
mediated loss of miR-34a expression in malignant peripheral nerve
sheath tumours. J Pathol. 220:58–70. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Kang MH and Reynolds CP: Bcl-2 inhibitors:
targeting mitochondrial apoptotic pathways in cancer therapy. Clin
Cancer Res. 15:1126–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Kostanova-Poliakova D and Sabova L:
Anti-apoptotic proteins-targets for chemosensitization of tumor
cells and cancer treatment. Neoplasma. 52:441–449. 2005.PubMed/NCBI
|
|
47.
|
Karnak D and Xu L: Chemosensitization of
prostate cancer by modulating Bcl-2 family proteins. Curr Drug
Targets. 11:699–707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Le LQ and Parada LF: Tumor
microenvironment and neurofibromatosis type I: connecting the GAPs.
Oncogene. 26:4609–4616. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Dai C, Santagata S, Tang Z, et al: Loss of
tumor suppressor NF1 activates HSF1 to promote carcinogenesis. J
Clin Invest. 122:3742–3754. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Edme N, Downward J, Thiery JP and Boyer B:
Ras induces NBT-II epithelial cell scattering through the
coordinate activities of Rac and MAPK pathways. J Cell Sci.
115:2591–2601. 2002.PubMed/NCBI
|
|
51.
|
Sevilla L, Zaldumbide A, Pognonec P and
Boulukos KE: Transcriptional regulation of the bcl-x gene encoding
the anti-apoptotic Bcl-xL protein by Ets, Rel/NFkappaB, STAT and
AP1 transcription factor families. Histol Histopathol. 16:595–601.
2001.PubMed/NCBI
|
|
52.
|
Lee J, Kannagi M, Ferrante RJ, Kowall NW
and Ryu H: Activation of Ets-2 by oxidative stress induces Bcl-xL
expression and accounts for glial survival in amyotrophic lateral
sclerosis. FASEB J. 23:1739–1749. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53.
|
Grad JM, Zeng XR and Boise LH: Regulation
of Bcl-xL: a little bit of this and a little bit of STAT. Curr Opin
Oncol. 12:543–549. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
54.
|
McCubrey JA, Steelman LS, Abrams SL, et
al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in
malignant transformation and drug resistance. Adv Enzyme Regul.
46:249–279. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55.
|
Sherman LS, Atit R, Rosenbaum T, Cox AD
and Ratner N: Single cell Ras-GTP analysis reveals altered Ras
activity in a subpopulation of neurofibroma Schwann cells but not
fibroblasts. J Biol Chem. 275:30740–30745. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
van Oosterwijk JG, Herpers B, Meijer D, et
al: Restoration of chemosensitivity for doxorubicin and cisplatin
in chondrosarcoma in vitro: BCL-2 family members cause
chemoresistance. Ann Oncol. 23:1617–1626. 2012.PubMed/NCBI
|
|
57.
|
Lieber J, Kirchner B, Eicher C, et al:
Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in
hepatoblastoma cells. Pediatr Blood Cancer. 55:1089–1095. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
Gottfried ON, Viskochil DH and Couldwell
WT: Neurofibromatosis type 1 and tumorigenesis: molecular
mechanisms and therapeutic implications. Neurosurg Focus.
28:E82010. View Article : Google Scholar : PubMed/NCBI
|
